Search results
Results From The WOW.Com Content Network
In addition to pharmaceutical companies (65 companies), Switzerland is home to many companies in the fields of biotechnology (338 companies) or medical devices and technology (341 companies). [4] [5] According to KPMG, there are 120 life science companies in Basel, 132 in Zürich and 92 in the Lemanic region. [4] [5]
Pages in category "Pharmaceutical companies of Switzerland" The following 27 pages are in this category, out of 27 total. This list may not reflect recent changes .
Multinational healthcare company headquartered in Basel. Subsidiaries include Genentech (US) and Ventana Medical Systems (US). 186 Novartis: $49,436 118,393 Multinational pharmaceutical company in Basel and one of the largest drug producers by both market cap and sales.
This listing is limited to those independent companies and subsidiaries notable enough to have their own articles in Wikipedia. Both going concerns and defunct firms are included, as well as firms that were part of the pharmaceutical industry at some time in their existence, provided they were engaged in the production of human (as opposed to veterinary) therapeutics.
Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Consistently ranked in the global top five, Novartis is one of the largest pharmaceutical companies in the world and was the fourth largest by revenue in 2022. [4] [5]
The following table lists the largest biotechnology and pharmaceutical companies ranked by revenue in billion USD. The change column indicates the company's relative position in this list compared to its relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
ZURICH and ZUG, Switzerland and STOCKHOLM, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Oncopeptides AB (STO: ONCO), a biotech company focused on difficult-to-treat cancers, and Veld Pharmaceuticals GmbH (“Veld”) and Slavpharma GmbH (“Slavpharma”) today announced a collaboration to commercialize Oncopeptides’ flagship drug Pepaxti (melphalan flufenamide) in Africa and Eurasia.
Roche is the only drug company authorized to manufacture the drug, which was discovered by Gilead Sciences. Roche purchased the rights to the drug in 1996, and in 2005, settled a royalty dispute, agreeing to pay Gilead tiered royalties of 14–22% of annual net sales without adjusting the payments for manufacturing costs, as had been allowed in ...